Stockscreener 앱 받기
5.92
1.99%
-0.12
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Momentum Shift: Does LARK stock benefit from AI growth2025 Price Momentum & Verified High Yield Trade Plans - baoquankhu1.vn
Myriad Genetics, Inc. (MYGN) Stock Analysis: Uncovering a 36.50% Potential Upside in the Diagnostics Sector - DirectorsTalk Interviews
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights - GlobeNewswire Inc.
Volume Summary: Is now the right time to enter Myriad Genetics IncMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn
What is Myriad Genetics Incs book value per share2025 Market Outlook & Daily Profit Focused Stock Screening - baoquankhu1.vn
MYRIAD GENETICS Q4 2025 Earnings Preview: Recent $MYGN Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Market Review: Can Myriad Genetics Inc. stock double in next 5 yearsOptions Play & Long-Term Safe Investment Ideas - Bộ Nội Vụ
TEM's Collab for Oncology Patient Population Is Gaining Attention - sharewise.com
The Technical Signals Behind (MYGN) That Institutions Follow - Stock Traders Daily
Myriad Genetics forecasts 2026 revenue growth of 6% to $870 million - Investing.com Canada
Myriad Genetics Reports Preliminary Q4 Revenue; Issues 2026 Guidance - Nasdaq
Myriad Genetics announces select preliminary fourth quarter and full year 2025 financial results and introduces full year 2026 financial guidance - marketscreener.com
Myriad Genetics Announces Select Preliminary Fourth Quarter And Full Year 2025 Financial Results And Introduces Full Year 2026 Financial Guidance - TradingView — Track All Markets
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Why Myriad Genetics Inc. stock is in analyst buy zoneJuly 2025 Institutional & Target Return Focused Stock Picks - ulpravda.ru
What Analysts Think Is Shaping The Story For Myriad Genetics (MYGN) Now - Yahoo Finance
Myriad Genetics, Inc. (MYGN) Investor Outlook: A 23.78% Potential Upside Amidst Diagnostic Innovation - DirectorsTalk Interviews
Can Myriad Genetics Inc. stock outperform in 2025 bull market2025 Short Interest & Growth-Oriented Investment Plans - ulpravda.ru
Is Myriad Genetics Inc. (MYD) stock a good hedge against inflationJuly 2025 Highlights & Capital Protection Trading Alerts - Улправда
Will Myriad Genetics Inc. stock benefit from infrastructure spending2025 Geopolitical Influence & Verified Trade Idea Suggestions - Улправда
Can Myriad Genetics Inc. (MYD) stock surprise with quarterly resultsQuarterly Investment Review & Consistent Return Strategy Ideas - Улправда
Clinical Laboratory Services Market is expected to reach US$ - openPR.com
Myriad Genetics (NASDAQ:MYGN) Stock Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Is Myriad Genetics Inc a good long term investmentMid Cap Growth Trends & Free Discover Massive Upside Stocks - earlytimes.in
The Truth About Myriad Genetics Inc: Is This DNA Stock a Sleeper Goldmine or Just Overhyped? - AD HOC NEWS
What analysts say about Myriad Genetics Inc stockPrice Gap Trading Strategies & Free Unmatched Market Gains - earlytimes.in
Should Myriad Genetics stock stay in your portfolio right now? - MSN
Myriad Genetics Inc Stock Analysis and ForecastHealthcare Stock Analysis & Small Investment Portfolio Tips - earlytimes.in
Precision Trading with Myriad Genetics Inc. (MYGN) Risk Zones - Stock Traders Daily
Should Myriad Genetics Stock Stay in Your Portfolio Right Now? - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Pancreatic Cancer Market is projected to reach US$ 5.7 billion - openPR.com
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Looking at the Narrative for Myriad Genetics After Price Target Revisions and Growth Concerns - Yahoo Finance
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz
Can Myriad Genetics Inc. stock sustain revenue growth2025 Macro Impact & Low Volatility Stock Recommendations - Улправда
Avoiding Lag: Real-Time Signals in (MYGN) Movement - news.stocktradersdaily.com
Myriad Genetics, Inc. $MYGN Shares Bought by Assenagon Asset Management S.A. - MarketBeat
What insider trading reveals about Myriad Genetics Inc. stockMarket Performance Recap & Intraday High Probability Alerts - Улправда
Sell Signal: Can Myriad Genetics Inc. (MYD) stock surprise with quarterly results2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - Улправда
Is Myriad Genetics Inc. stock vulnerable to regulatory risksEarnings Overview Report & AI Powered Market Entry Strategies - Улправда
Will Myriad Genetics Inc. stock attract more institutional investorsWeekly Trend Recap & Capital Efficient Trading Techniques - Улправда
Myriad Genetics, Inc. (NASDAQ:MYGN) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛
Zydus Lifesciences signs agreement with Myriad Genetics for cancer-risk tests in India - marketscreener.com
J.P. Morgan Healthcare Conference - marketscreener.com
Parp Inhibitor Biomarkers Market Forecast Through 2032 - openPR.com
Cancer Diagnostics Market is Going to Boom: New Report Reveals - openPR.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Myriad Genetics Earnings Notes - Trefis
2.51%
0.74%
자본화:
|
볼륨(24시간):